share_log

公告精选 | 小米Q1经调整净利同比翻番;哔哩哔哩Q1调整后亏损同比收窄56%

Featured announcements | Xiaomi Q1's adjusted net profit doubled year on year; Bilibili Q1's adjusted loss narrowed 56% year on year

cls.cn ·  May 24 08:05

① NetEase's net profit rose more than 10% in the first quarter. How was the revenue performance? ② Bilibili's loss narrowed by 56% after adjustment in the first quarter. What are the highlights of the business growth rate?

Important announcements for Hong Kong stocks yesterday and this morning

1) Company news

$XIAOMI-W (01810.HK)$: Revenue of 75.507 billion yuan was obtained in the first quarter, up 27% year on year; adjusted net profit was 6.491 billion yuan, up 100.8% year on year.

$BILIBILI-W (09626.HK)$: Net operating income for the first quarter was $5.665 billion, up 12% year on year; net loss for the first quarter was $765 million, up 21.4% from loss of 630 million yuan in the same period last year (the year-on-year increase was mainly due to income from debt offsetting recorded in the first quarter of 2023 of RMB 336 million); adjusted net loss was RMB 456 million, a decrease of 56% year on year.

During the period, value-added service revenue was 2,529 billion yuan, up 17% year on year; advertising revenue was 1,669 billion yuan, up 31% year on year. Monthly active users reached a new high of 341.5 million in the first quarter, an increase of 8% over the previous year; the average daily usage time of users reached 105 minutes, a record high.

$BEKE-W (02423.HK)$: Net revenue for the first quarter was 16.4 billion yuan, down 19.2% year on year; adjusted net profit was 1,392 billion yuan.

The total transaction volume for the first quarter was 629.9 billion yuan, down 35.2% year on year; stock housing transactions were 453.2 billion yuan, down 31.8% year on year; new housing transactions were 151.8 billion yuan, down 45.4% year on year.

As of March 31, 2024, the number of active stores was 42,593, up 7.5% year on year; the number of active agents was 399,200, a decrease of 3.0% year on year.

$NTES-S (09999.HK)$: Net revenue for the first quarter was 26.9 billion yuan, up 7.2% year on year; net profit was 7.6 billion yuan, up 13% year on year.

In the first quarter, net revenue from games and related value-added services was $21.5 billion, up 7.0% year on year; Youdao's net revenue was $1.4 billion, up 19.7% year on year;$CLOUD MUSIC (09899.HK)$Net revenue was 2 billion yuan, up 3.6% year on year; net revenue from innovation and other businesses was 2 billion yuan, up 6.1% year on year.

$WB-SW (09898.HK)$: Net revenue for the first quarter was US$395.5 million, down 4% year on year; net profit was US$494.38 million, down 50.8% year on year.

As of March 2024, the number of monthly active users was 588 million, and the average number of daily active users was 255 million; the total amount of cash, cash equivalents and short-term investments was US$3.3 billion.

In the period, advertising and marketing revenue for the first quarter of 2024 was US$339 million, down 5% year on year; revenue from value-added services was US$56.5 million, down 3% year on year.

$UBoT Holding Ltd (810385.HK)$It plans to sell 125 million shares and is expected to be listed on June 3.

$PARKSON GROUP (03368.HK)$: Operating revenue for the first quarter was 1,053 billion yuan, a year-on-year decrease of 4.81%; net profit was 19.081 million yuan, a decrease of 28.3% year-on-year.

$SINO BIOPHARM (01177.HK)$: A phase III study of bemosubimab injection combined with anlotinib hydrochloride capsules for first-line treatment of advanced renal cell carcinoma obtained positive results.

$KEYMED BIO-B (02162.HK)$: Spuquipimab injections were included in the priority review and approval process for the treatment of chronic sinusitis with nasal polyps.

$GENSCRIPT BIO (01548.HK)$$Legend Biotech (LEGN.US)$The 2024 Annual Meeting of the American Society of Clinical Oncology and the European Hematology Association will announce the latest data on CARVYKTI for the treatment of patients with multiple myeloma.

$LEPU BIO-B (02157.HK)$: The results of the three clinical studies were presented at the 2024 ASCO Annual Meeting.

$SKB BIO-B (06990.HK)$: The research results of the core product, lucan satuzumab (sAC-TMT), were announced at the 2024 American Society of Clinical Oncology Annual Meeting.

2) Repurchase news

$TENCENT (00700.HK)$: HK$1.03 billion was spent to repurchase 2.63 million shares at a repurchase price of HK$376.4-383.8.

$HSBC HOLDINGS (00005.HK)$: Approximately HK$243 million was spent to repurchase 3.496,800 shares at a repurchase price of HK$69.05 to HK$69.5.

$HANG SENG BANK (00011.HK)$: A repurchase of 300,000 shares was spent at HK$338.563 million, at a repurchase price of HK$111.7-114.9.

$TECHTRONIC IND (00669.HK)$: Spend HK$248.90,800 to repurchase 250,000 shares at a repurchase price of HK$99.2-100.2.

$CHINASOFT INT'L (00354.HK)$: Spend HK$21.833,400 to repurchase 5 million shares at a repurchase price of HK$4.33-4.39.

$AIA (01299.HK)$: A repurchase of 250,000 shares was spent at HK$15.455,200, at a repurchase price of HK$61.5-62.6.

edit/ruby

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment